AIIMS - All India Institute Of Medical Science

Doctor's Name : First Doctor, First Doctor,
Hospital Name : AIIMS - All India Institute Of Medical Science
Court Case : case no. 331
Contact Detail :  Call: 011-4425587

Target Audience and Goal Statement

The target audience of this activity is primary care physicians, endocrinologists, and other healthcare professionals who treat people with diabetes and its related conditions.

This activity will investigate the role of insulin resistance in the development and course of type 2 diabetes, cardiovascular disease and stroke and explore the extent and nature of these risk factors in common racial/ethnic groups in the US, identifying and incorporating culturally oriented strategies in the design of appropriate diabetes management plans.

Participants will be provided with clinically relevant, evidence-based information. At the completion of the activity, the participant should be able to:

  1. Identify mechanisms by which insulin resistance is associated with type 2 diabetes, abdominal obesity, hypertension, dyslipidemia and endothelial dysfunction and the central role insulin resistance plays in the genesis of metabolic and vascular abnormalities;
  2. Describe the role that agents that reduce insulin resistance play in the management of type 2 diabetes, coronary artery disease and stroke risk reduction, based upon information derived from recent clinical trials;
  3. Develop treatments that decrease insulin resistance into a risk-reducing treatment program to potentially decrease macrovascular disease in high-risk individuals;
  4. Identify the main biological, medical, and cultural factors influencing the development of type 2 diabetes, the metabolic syndrome, cardiovascular disease, and stroke in minority racial/ethnic groups;
  5. Incorporate practical aspects of cultural competence in clinical encounters with patients from various ethnic and racial backgrounds.


As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of non-profit or government organizations and non-healthcare related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.